AGIO
AGIOS PHARMACEUTICALS, INC.
$29.46
+2.58%
$1.8B
No data for this timeframe.
Vol
Market Cap$1.8B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders50 funds
Inst. Value$1.4B
Inst. Activity14 buys / 16 sells
Insider Activity0B / 8S
Insider Net $-$1.2M
SEC Reports5
Press Releases3
Congressional1 trades
Recent Activity
Jun 13, 2026
fda
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Agios showcases RISE UP Phase 3 results at EHA 2026 Plenary Session reinforcing strong anti-hemolyti
Apr 29, 2026
SEC
Agios reported Q1 2026 revenue of $20.7M, more than doubling from $8.7M a year ago, driven by the U.S. launch of AQVESME
8-K — Impact 5/10
Apr 29, 2026
SEC
Agios Pharmaceuticals reported Q1 2026 revenue of $20.7M (beat $13.6M consensus by 53%) and EPS of -$1.69 (beat -$1.79 c
PRESS-RELEASE — Impact 6/10
Apr 24, 2026
SEC
Agios Pharmaceuticals has filed a definitive proxy statement (DEFA14A) for an upcoming shareholder meeting. This is a ro
DEFA14A — Impact 2/10
Apr 22, 2026
Event
AQVESME
WARNING: HEPATOCELLULAR INJURY AQVESME can cause serious hepatocellular injury. Measure liver labora
Apr 2, 2026
Insider
Burns James William sold 3,280 shares
Chief Legal Officer @ $34.71 ($113.8K)
Apr 2, 2026
Insider
Burns James William acquired via exercise 8,500 shares
Chief Legal Officer
Apr 2, 2026
Insider
Gheuens Sarah sold 2,940 shares
Chief Medical Officer @ $34.71 ($102.0K)
Price Targets
$40.25
+36.6% upside
Strong Buy
Current $29.46
Low $28.00
Median $38.00
High $59.00
8 analysts
$28.00
$59.00
Analyst Ratings
5Strong Buy
7Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | JP Morgan | MAINTAIN | Neutral → Neutral |
| May 29, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| Apr 30, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Apr 21, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| Apr 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.67 ▼ -6.1% | $-2.01 — $-1.48 | 13% YoY | 8 |
| Next Q | $-1.49 ▼ -2.2% | $-1.78 — $-1.31 | 16% YoY | 10 |
| Current FY | $-6.18 ▼ -3.5% | $-7.21 — $-5.50 | 13% YoY | 8 |
| Next FY | $-4.77 ▼ -2.0% | $-6.16 — $-3.84 | 23% YoY | 10 |
Latest Reports
MIXED
Press
7/10
Agios presented detailed Phase 3 RISE UP data for mitapivat in sickle cell disease at EHA 2026, showing statistically si
Jun 13, 2026
NEUTRAL
8-K
5/10
Agios reported Q1 2026 revenue of $20.7M, more than doubling from $8.7M a year ago, driven by the U.S. launch of AQVESME
Apr 29, 2026
BULLISH
PRESS-RELEASE
6/10
Agios Pharmaceuticals reported Q1 2026 revenue of $20.7M (beat $13.6M consensus by 53%) and EPS of -$1.69 (beat -$1.79 c
Apr 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $194.7M | — |
| FARALLON CAPITAL MANAGEMENT LLC | $192.3M | — |
| STATE STREET CORP | $113.7M | ADD |
| D. E. Shaw & | $90.7M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $89.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 2, 2026 | Burns James | SELL | $113.8K |
| Apr 2, 2026 | Burns James | M | $0.00 |
| Apr 2, 2026 | Gheuens Sarah | SELL | $102.0K |
| Apr 2, 2026 | Gheuens Sarah | M | $0.00 |
| Apr 2, 2026 | Jones Cecilia | SELL | $109.0K |
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
50 institutional holders with $1.4B total value (40,643,264 shares) as of 2026-Q1. Top holders: BlackRock,, FARALLON, STATE. Net selling activity: 16 institutions trimmed/exited vs 14 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5,754,957 | $194.7M | 14.3% | — |
| 2 | FARALLON CAPITAL MANAGEMENT LLC | 5,684,000 | $192.3M | 14.1% | — |
| 3 | STATE STREET CORP | 3,364,879 | $113.7M | 8.3% | ADD +37.4% |
| 4 | D. E. Shaw & Co., Inc. | 2,681,169 | $90.7M | 6.7% | DOUBLED +399.6% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,632,316 | $89.1M | 6.5% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,611,035 | $88.3M | 6.5% | — |
| 7 | Erste Asset Management GmbH | 2,704,900 | $80.1M | 5.9% | — |
| 8 | BNP Paribas Asset Management Holding S.A. | 1,580,840 | $53.5M | 3.9% | — |
| 9 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1,494,435 | $50.6M | 3.7% | — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,344,953 | $45.5M | 3.3% | — |
| 11 | DIMENSIONAL FUND ADVISORS LP | 1,151,614 | $38.9M | 2.9% | — |
| 12 | MORGAN STANLEY | 967,525 | $32.7M | 2.4% | DOUBLED +114.4% |
| 13 | GOLDMAN SACHS GROUP INC | 805,776 | $27.3M | 2.0% | — |
| 14 | Nuveen, LLC | 722,348 | $24.4M | 1.8% | DOUBLED +142.5% |
| 15 | WELLINGTON MANAGEMENT GROUP LLP | 641,486 | $21.7M | 1.6% | NEAR_EXIT -75.8% |
| 16 | CITADEL ADVISORS LLC | 619,613 | $21.0M | 1.5% | — |
| 17 | BANK OF AMERICA CORP /DE/ | 507,900 | $17.2M | 1.3% | TRIM -52.3% |
| 18 | Artisan Partners Limited Partnership | 481,516 | $16.3M | 1.2% | ADD +25.2% |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 477,032 | $16.1M | 1.2% | — |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 450,093 | $15.2M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Nuveen, LLC | DOUBLED | 297,908 | 722,348 | +142.5% | $24.4M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 353,639 | 448,118 | +26.7% | $15.2M | 2026-Q1 |
| Legal & General Group Plc | ADD | 328,211 | 423,915 | +29.2% | $14.3M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 79,840 | 238,468 | +198.7% | $8.1M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | DOUBLED | 35,788 | 129,531 | +261.9% | $4.4M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 205,019 | 128,814 | -37.2% | $3.8M | 2026-Q1 |
| Trexquant Investment LP | TRIM | 226,600 | 75,298 | -66.8% | $2.5M | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 110,440 | 67,153 | -39.2% | $2.3M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 14,352 | 63,550 | +342.8% | $2.1M | 2026-Q1 |
| Hudson Bay Capital Management LP | TRIM | 100,000 | 51,830 | -48.2% | $1.8M | 2026-Q1 |
| DEUTSCHE BANK AG\ | TRIM | 122,875 | 50,384 | -59.0% | $1.7M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | 70,256 | 50,046 | -28.8% | $1.7M | 2026-Q1 |
| Capital International Investors | NEAR_EXIT | 703,865 | 48,616 | -93.1% | $1.6M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 24,679 | 39,710 | +60.9% | $1.3M | 2026-Q1 |
| Brevan Howard Capital Management LP | ADD | 19,336 | 24,469 | +26.5% | $866.6K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 18,200 | 24,400 | +34.1% | $825.5K | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 57,292 | 23,732 | -58.6% | $802.9K | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 27,697 | 19,115 | -31.0% | $646.7K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEAR_EXIT | 635,069 | 18,009 | -97.2% | $609.2K | 2026-Q1 |
| Rockefeller Capital Management L.P. | NEAR_EXIT | 211,428 | 14,875 | -93.0% | $503.2K | 2026-Q1 |
| NOMURA HOLDINGS INC | TRIM | 12,355 | 9,176 | -25.7% | $310.4K | 2026-Q1 |
| FMR LLC | TRIM | 24,334 | 9,121 | -62.5% | $308.6K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | NEAR_EXIT | 81,055 | 9,045 | -88.8% | $306.0K | 2026-Q1 |
| CWM, LLC | DOUBLED | 484 | 1,281 | +164.7% | $43.3K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 300 | 950 | +216.7% | $32.1K | 2026-Q1 |
7 unique insiders with 34 transactions. Net insider value: -$1.2M ($0.00 bought, $1.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | Burns James William | Chief Legal Officer | SELL | 3,280 | $34.71 | $113.8K |
| Apr 2, 2026 | Burns James William | Chief Legal Officer | EXERCISE | 8,500 | — | — |
| Apr 2, 2026 | Gheuens Sarah | Chief Medical Officer | SELL | 2,940 | $34.71 | $102.0K |
| Apr 2, 2026 | Gheuens Sarah | Chief Medical Officer | EXERCISE | 8,500 | — | — |
| Apr 2, 2026 | Jones Cecilia | Chief Financial Officer | SELL | 3,141 | $34.71 | $109.0K |
| Apr 2, 2026 | Jones Cecilia | Chief Financial Officer | EXERCISE | 8,500 | — | — |
| Apr 2, 2026 | Milanova Tsveta | Chief Commercial Officer | SELL | 3,262 | $34.71 | $113.2K |
| Apr 2, 2026 | Milanova Tsveta | Chief Commercial Officer | EXERCISE | 8,500 | — | — |
| Apr 2, 2026 | Viswanadhan Krishnan | Chief Corp Dev & Strategy | SELL | 2,959 | $34.71 | $102.7K |
| Apr 2, 2026 | Viswanadhan Krishnan | Chief Corp Dev & Strategy | EXERCISE | 8,100 | — | — |
| Apr 2, 2026 | Goff Brian | Chief Executive Officer | SELL | 12,472 | $34.71 | $432.9K |
| Apr 2, 2026 | Goff Brian | Chief Executive Officer | EXERCISE | 25,528 | — | — |
| Mar 5, 2026 | Viswanadhan Krishnan | Chief Corp Dev & Strategy | EXERCISE | 8,100 | — | — |
| Mar 5, 2026 | Viswanadhan Krishnan | Chief Corp Dev & Strategy | SELL | 2,959 | $27.80 | $82.3K |
| Mar 3, 2026 | Washburn Theodore James Jr. | Principal Accounting Officer | SELL | 5,272 | $28.88 | $152.3K |
| Mar 2, 2026 | Goff Brian | Chief Executive Officer | EXERCISE | 8,500 | — | — |
| Mar 2, 2026 | Gheuens Sarah | Chief Medical Officer | EXERCISE | 4,000 | — | — |
| Mar 2, 2026 | Jones Cecilia | Chief Financial Officer | EXERCISE | 2,000 | — | — |
| Mar 2, 2026 | Milanova Tsveta | Chief Commercial Officer | EXERCISE | 5,666 | — | — |
| Mar 2, 2026 | Washburn Theodore James Jr. | Principal Accounting Officer | EXERCISE | 2,350 | — | — |
| Mar 2, 2026 | Burns James William | Chief Legal Officer | EXERCISE | 4,000 | — | — |
| Mar 1, 2026 | Viswanadhan Krishnan | Chief Corp Dev & Strategy | AWARD | 14,000 | — | — |
| Mar 1, 2026 | Viswanadhan Krishnan | Chief Corp Dev & Strategy | AWARD | 52,000 | — | — |
| Mar 1, 2026 | Goff Brian | Chief Executive Officer | AWARD | 48,000 | — | — |
| Mar 1, 2026 | Gheuens Sarah | Chief Medical Officer | AWARD | 14,000 | — | — |
| Mar 1, 2026 | Gheuens Sarah | Chief Medical Officer | AWARD | 52,000 | — | — |
| Mar 1, 2026 | Milanova Tsveta | Chief Commercial Officer | AWARD | 14,000 | — | — |
| Mar 1, 2026 | Washburn Theodore James Jr. | Principal Accounting Officer | AWARD | 8,452 | — | — |
| Mar 1, 2026 | Goff Brian | Chief Executive Officer | AWARD | 174,000 | — | — |
| Mar 1, 2026 | Burns James William | Chief Legal Officer | AWARD | 14,000 | — | — |
| Mar 1, 2026 | Burns James William | Chief Legal Officer | AWARD | 52,000 | — | — |
| Mar 1, 2026 | Jones Cecilia | Chief Financial Officer | AWARD | 14,000 | — | — |
| Mar 1, 2026 | Jones Cecilia | Chief Financial Officer | AWARD | 52,000 | — | — |
| Mar 1, 2026 | Milanova Tsveta | Chief Commercial Officer | AWARD | 52,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.8/10.
NEUTRAL
8-K
5/10
Agios reported Q1 2026 revenue of $20.7M, more than doubling from $8.7M a year ago, driven by the U.
Apr 29, 2026
BULLISH
PRESS-RELEASE
6/10
Agios Pharmaceuticals reported Q1 2026 revenue of $20.7M (beat $13.6M consensus by 53%) and EPS of -
Apr 29, 2026
NEUTRAL
DEFA14A
2/10
Agios Pharmaceuticals has filed a definitive proxy statement (DEFA14A) for an upcoming shareholder m
Apr 24, 2026
NEUTRAL
PRESS-RELEASE
3/10
Agios Pharmaceuticals announced it will report Q1 2026 financial results on April 29, 2026, but prov
Apr 6, 2026
NEUTRAL
CLUSTER
3/10
Two insiders at Agios Pharmaceuticals sold shares in the past week, including the Chief Corporate De
Mar 9, 2026
MIXED
7/10
Agios presented detailed Phase 3 RISE UP data for mitapivat in sickle cell disease at EHA 2026, show
Jun 13, 2026
MIXED
6/10
Agios Pharmaceuticals licensed exclusive global rights to cevidoplenib, a next-generation oral SYK i
Jun 1, 2026
BEARISH
6/10
Agios Pharmaceuticals announced it will not advance tebapivat, its next-generation oral PK activator
May 29, 2026
Current analyst consensus: Buy (75% buy). Based on 16 analysts: 5 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$40.25 mean target
+36.6% upside
Strong Buy (1.60)
$28.00 Low
$59.00 High
| Metric | Value |
|---|---|
| Current Price | $29.46 |
| Target Low | $28.00 |
| Target Mean | $40.25 |
| Target Median | $38.00 |
| Target High | $59.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.67 | $-2.01 | $-1.48 | 13.3% | -6.1% | 0↑ 1↓ | $0.0B | 111.8% | 8 |
| Next Q 2026-09-30 |
$-1.49 | $-1.78 | $-1.31 | 16.1% | -2.2% | 1↑ 0↓ | $0.0B | 159.8% | 10 |
| Current FY 2026-12-31 |
$-6.18 | $-7.21 | $-5.50 | 13.2% | -3.5% | 0↑ 1↓ | $0.1B | 125.6% | 8 |
| Next FY 2027-12-31 |
$-4.77 | $-6.16 | $-3.84 | 23.4% | -2.0% | 1↑ 1↓ | $0.3B | 110.6% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.673 | |
| 7d ago | $-1.644 | -0.029 |
| 30d ago | $-1.576 | -0.097 |
| 60d ago | $-1.685 | +0.012 |
| 90d ago | $-1.697 | +0.024 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| May 29, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Apr 30, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Apr 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 6, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Apr 1, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Mar 5, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Dec 26, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Dec 24, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 24, 2025 | B of A Securities | MAINTAIN | Buy | Buy |
| Dec 24, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 7 | 4 | 0 | 0 | 75% | |
| May 1, 2026 | 5 | 7 | 4 | 0 | 0 | 75% | |
| Apr 1, 2026 | 5 | 7 | 4 | 0 | 0 | 75% | |
| Mar 1, 2026 | 5 | 7 | 4 | 0 | 0 | 75% | |
| Feb 1, 2026 | 5 | 7 | 4 | 0 | 0 | 75% | |
| Jan 1, 2026 | 5 | 7 | 4 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Agios Pharmaceuticals Inc | Apr 8, 2026 (37d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 13, 2026
fda
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Agios showcases RISE UP Phase 3 results at EHA 2026 Plenary Session reinforcing strong anti-hemolytic profile of mitapivat in sickle cell disease
Jun 1, 2026
contract
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Agios announces an agreement with Oscotec to license the exclusive global rights to cevidoplenib, a novel, next generation, oral SYK inhibitor
May 29, 2026
fda
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Agios provides update on Phase 2b trial of tebapivat in lower-risk myelodysplastic syndromes
May 22, 2026
other
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
PYRUKYND (mitapivat) approved in the European Union for adults with thalassemia
May 12, 2026
other
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
Agios announces the submission of its sNDA to the FDA for the U.S. accelerated approval of mitapivat in sickle cell disease
May 12, 2026
other
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
Agios announces new data on mitapivat will be featured in oral and poster presentations at EHA 2026 in Stockholm, Sweden, June 11-14, 2026
May 2, 2026
Clinical Trial
A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency
Phase Phase 2 — COMPLETED
Apr 29, 2026
earnings
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
Agios announces first quarter 2026 financial results and provides business update.
Apr 29, 2026
earnings_calendar
AGIO Q1 2026 Earnings Scheduled — 2026-04-29
Apr 22, 2026
FDA
AQVESME
WARNING: HEPATOCELLULAR INJURY AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase, and to
Apr 6, 2026
earnings
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Agios will report its first quarter 2026 financial results and business highlights on Wednesday, April 29, 2026.
Mar 31, 2026
short_volume
Short Volume: AGIO — 58.1% short (0.9M / 1.5M)
Short: 883,872 | Exempt: 1,585 | TRF Vol: 1,522,539 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
short_volume
Short Volume: AGIO — 89.3% short (0.5M / 0.5M)
Short: 450,696 | Exempt: 1,622 | TRF Vol: 504,947 | Short Ratio: 89.3% | Off-exchange volume (dark pool + OTC)
Dec 7, 2025
fda_pdufa
PDUFA: AGIO — PYRUKYND in non transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia — 2025-12-07
FDA target action date 2025-12-07 for AGIO (AGIOS PHARMACEUTICALS, INC.). Drug: PYRUKYND. Indication: non transfusion-dependent and transfusion-depend